Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736537 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRMAPK1PDE7A | |
| SCHEMBL28833103 | 0.80 | MAP4K4 (0.44) | ALDH1A1TDP1TSHRMAPK1PDE7A | |
| SCHEMBL28720537 | 0.77 | TSHR (0.48) | ALDH1A1TDP1TSHRMAPTLMNA | |
| SCHEMBL3862889 | 0.75 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL5700377 | 0.75 | GABRA1 (0.37) | ALDH1A1TDP1TSHRL3MBTL1KMT2A | |
| SCHEMBL7697285 | 0.75 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRMAPK1POLB | |
| SCHEMBL652346 | 0.75 | MEN1 (0.39) | ALDH1A1TDP1POLBPDE4DL3MBTL1 | |
| SCHEMBL7985686 | 0.75 | GABRA1 (0.37) | ALDH1A1TDP1TSHRPOLBL3MBTL1 | |
| SCHEMBL19791860 | 0.75 | TDP1 (0.44) | ALDH1A1TDP1POLBL3MBTL1KMT2A | |
| SCHEMBL3614808 | 0.75 | ALDH1A1 (0.42) | ALDH1A1TDP1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4665331-A1 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250100995-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2025-03-27 | — | — | US | disclosed |
| CN-119462492-A | Method for preparing 3-pyridyl-2-methyl naphthoate compound by catalysis | 湖州学院 | 2025-02-18 | — | — | CN | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024173219-A1 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-118434727-A | Substituted pyrimidinone derivatives, pharmaceutical compositions and pharmaceutical uses thereof | 上海海雁医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-117654560-B | Method for continuously preparing nitro compound by oxidizing amino | 安徽泽升科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4359406-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Celgene Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| US-7612218-B2 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20080064878-A1 | Low cost, high yield, industrial scale reaction of 4-halopyridine and indole derivatives in presence of strong organic base; heavy metal catalyst free | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064878-A1 | Low cost, high yield, industrial scale reaction of 4-halopyridine and indole derivatives in presence of strong organic base; heavy metal catalyst free | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1897875-A1 | Process for producing 1-pyridin-4-YL-indoles | Fujifilm Finechemicals Co. Ltd. (JP) | 2008-03-12 | — | — | EP | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100995-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | ALDH1A1 709/4885TDP1 2678/4885TSHR 883/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | ALDH1A1 3867/4885TDP1 3909/4885TSHR 3422/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | ALDH1A1 3993/4885TDP1 4088/4885TSHR 2980/4885 |
| US-20080064878-A1 | Low cost, high yield, industrial scale reaction of 4-halopyridine and indole derivatives in presence of strong organic base; heavy metal catalyst free | IDO1, IDO2, TDO2 | ALDH1A1 639/4885TDP1 1515/4885TSHR 1238/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | ALDH1A1 4740/4885TDP1 2107/4885TSHR 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.